Images List Premium Download Classic

Breast Cancer

Breast Cancer-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Dcis recurrence and invasive breast cancer
Prelude, Inc.
December 07, 2017 - N°20170350895

The present technology generally relates to methods and compositions relevant to the prediction that a subject with and/or after treatment for dcis will experience a subsequent ipsilateral breast event that is a dcis recurrence, an invasive breast cancer, both a dcis recurrence and invasive cancer, or neither. The technology can assist one with how to treat such subjects.
Mir-125a-5p as a biomarker for breast cancer
Kaohsiung Medical University
December 07, 2017 - N°20170349955

A method for predicting a survival rate of a breast cancer patient, including: providing a biological sample of the breast cancer patient; measuring mir-125a-5p expression level in the biological sample; and comparing the mir-125a-5p expression level in the biological sample of the breast cancer patient with mir-125a-5p expression level in another biological sample of ...
Quinoline derivative
Ono Pharmaceutical Co., Ltd.
December 07, 2017 - N°20170349583

A compound represented by general formula (i) and having a quinoline skeleton has a strong axl inhibitory activity, and therefore the compound can be an agent for treating axl-related diseases, for example, cancer such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.
Breast Cancer Patent Pack
Download 198+ patent application PDFs
Breast Cancer Patent Applications
Download 198+ Breast Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 198+ full patent PDF documents of Breast Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and ...
Pimco 2664 Limited
December 07, 2017 - N°20170349551

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e. G., diseases) including, inflammation and/or joint destruction ...
Drug delivery polymers and uses thereof
Massachusetts Institute Of Technology
December 07, 2017 - N°20170348431

Described herein are platinum-based brush-arm star polymers (pt-basps), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as oxaliplatin. Also provided are methods and kits involving the pt-basps, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e. G., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, colorectal cancer, liver cancer, ...
Adherent cancer cell line expressing a hematological tumor antigen
Forevertek Biotechnology Co., Ltd.
December 07, 2017 - N°20170348403

The present invention relates to a transduced cancer cell line stably expressing a leukemia tumor antigen, wherein the cancer cell line is cervical cancer cells, breast cancer cells, ovarian cancer cells, pancreatic cancer cells, lung cancer cells, or glioblastoma cells. The transduced adherent cell line of the present invention is useful for many pre-clinical applications such as real time cytotoxicity ...
Breast Cancer Patent Pack
Download 198+ patent application PDFs
Breast Cancer Patent Applications
Download 198+ Breast Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 198+ full patent PDF documents of Breast Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method of prognosing and predicting breast cancer recurrence, markers employed therein and kit thereof
Oncostem Diagnostics (mauritius) Pvt. Ltd.
November 30, 2017 - N°20170343548

The present disclosure relates to a method of prognosing and predicting breast cancer recurrence in patients, more particularly, the present disclosure relates to a method of prognosing which stratifies early stage er+/pr+ and her2− breast cancer patients with invasive ductal/lobular carcinoma of the breast into low risk or high risk for breast cancer recurrence by employing an ...
Device, system and method for cancer prognosis and uses thereof
Cedars-sinai Medical Center
November 30, 2017 - N°20170342506

Modules, devices, systems and methods for measuring or detecting cysteine and/or methionine metabolite levels in a sample from a subject are disclosed. Various embodiments of the present invention concern modules, devices, systems and methods for prognosing or diagnosing cancer, for example, prostate, colon, ovarian or breast cancer; predicting the risk or probability of cancer recurrence; and/or for predicting, ...
Biomarkers for breast cancer and methods of use thereof
Wisconsin Alumni Research Foundation
November 30, 2017 - N°20170342502

Described herein is the use of agouti signaling protein (asip), in addition to certain other melanocortin signaling network (msn) genes, as prognostic and predictive biomarkers for the progression of breast cancer. In particular, the novel biomarkers can be used to determine if a female breast cancer patient is at risk of progressing to metastatic disease and thus also be used ...
Hla-dr binding peptides and their uses
University Of Washington
November 30, 2017 - N°20170342126

The present invention provides hla-dr (mhc class ii) binding peptides derived from the ovarian/breast cancer associated antigens, human epidermal growth factor receptor 2 (her-2/neu), carcinoembryonic antigen (cea), insulin growth factor binding protein 2 (igfbp-2), and cyclin d1. The immunogenic peptides can be used in cancer vaccines.
Photoactivatable caged tamoxifen and tamoxifen derivative molecules and methods of use thereof
The General Hospital Corporation
November 30, 2017 - N°20170340736

Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell ...
Use of an antimicrobial peptide tp4 in treating a cancer
Academia Sinica
November 30, 2017 - N°20170340700

The preset invention relates to a new approach for treating a cancer, particularly a malignant tumor, a multidrug-resistant (mdr) cancer, a recurrent cancer or a metastatic cancer, using a specific cationic antimicrobial peptide (cap), tilapia piscidin 4 (tp4), which is derived from nile tilapia (oreochromis niloticus). Also provided is a method for treating a breast cancer, particularly triple negative breast cancer (...
Masitinib combination for use in treating breast cancer
Ab Science
November 30, 2017 - N°20170340629

Disclosed is a method for treating breast cancer in a subject in need thereof, including administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with a therapeutically effective amount of a chemotherapeutic agent.
Breast Cancer Patent Pack
Download 198+ patent application PDFs
Breast Cancer Patent Applications
Download 198+ Breast Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 198+ full patent PDF documents of Breast Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
Abraxis Bioscience, Llc
November 30, 2017 - N°20170340599

The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention ...
Bruton's tyrosine kinase as anti-cancer drug target
The Research Foundation For The State University Of New York
November 23, 2017 - N°20170335011

Receptor protein kinases (rptks) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over 5 half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using rna interference in the clinically relevant erb-b2 positive, bt474 breast ...
Tetravalent tlr9 bispecific antibody
H. Lee Moffitt Cancer Center And Research Institute, Inc.
November 23, 2017 - N°20170335009

Disclosed are compositions and methods for targeted treatment of tlr9-expressing cancers, such as primary human mds progenitors and hematopoietic stem cell (hsc), as well as lung and breast cancers. In particular, multispecific, multivalent antibodies are disclosed that are able to engage t-cells to destroy tlr9-expressing malignant cells.
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
November 23, 2017 - N°20170334879

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, ...
Prodrugs of riluzole and their method of use
Rutgers, The State University Of New Jersey
November 23, 2017 - N°20170334870

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic ...
Pharmaceutical composition for adjunctively treating cancer
Taipei Medical University
November 23, 2017 - N°20170333502

The present invention provides a pharmaceutical composition for adjunctively treating cancer. Differing from conventional therapies commonly using anti-cancer drugs and/or radiation substances to cause the apoptosis of cancer cells, the present invention particularly adopts an ethanol extract of taiwanofungus camphorata (tcee), an ethanol extract of ganoderma lucidum (glee) or a combination of the tcee and the glee as the ...
Methods of reducing mammographic breast density and/or breast cancer risk
Havah Therapeutics Pty Ltd.
November 23, 2017 - N°20170333445

The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-memopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed ...
Vaginal delivery systems containing selective estrogen receptor modulator (serm) and uses thereof
Azure Biotech, Inc.
November 23, 2017 - N°20170333394

The present disclosure provides pharmaceutical compositions that include one or more selective estrogen receptor modulator(s) (serm(s), e. G., lasofoxifene) and four or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be able to form nanodroplets (e. G., by self-nanoemulsifying) in vaginal fluid and to deliver the one or more serm(s) to the vagina of a female subject. ...
Loading